New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
12:23 EDTTKPYY, FURXFuriex confirms Takeda's NDA submission for Trelagliptin Succinate in Japan
Furiex Pharmaceuticals (FURX) confirmed that Takeda Pharmaceutical Company Limited (TKPYY) announced that it has submitted a New Drug Application, or NDA, to the Japanese Ministry of Health, Labour and Welfare for trelagliptin succinate, a once weekly dosage treatment for type 2 diabetes. Under Furiex’s agreement with Takeda, Furiex is eligible to receive royalties and sales-based milestones if trelagliptin succinate is approved and marketed in Japan.
News For FURX;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
19:48 EDTTKPYYEli Lilly responds to ruling in Takeda case
Eli Lilly (LLY) issued the following statement in response to a judge's ruling that the punitive damages awarded in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals (TKPYY) be reduced. The judge reduced the punitive damages from $3B for Lilly and $6B for Takeda to $9.2M for Lilly and $27.6M for Takeda. Plaintiffs also were awarded $1.27M in compensatory damages. The allocation of liability was 75% Takeda, 25% Lilly. "While we have empathy for the plaintiff, we believe the evidence did not support his claims," said Mike Harrington, senior VP and general counsel, Lilly. "We will continue working vigorously to overturn the verdict."
18:45 EDTTKPYYTakeda Pharmaceutical Co. Ltd. reponds to ruling in diabetes drug case
Subscribe for More Information
17:31 EDTTKPYYEli Lilly, Takeda have Actos award cut to $36.8M from $9B, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use